Endophthalmitis Clinical Trial
Verified date | November 2006 |
Source | hahid Beheshti University of Medical Sciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | Iran: Ethics Committee |
Study type | Interventional |
Purpose: To evaluate the efficacy of combined intraocular injection of gentamycin and
clindamycin in prevention of acute posttraumatic bacterial endophthalmitis (APBE) following
penetrating eye injuries.
Design: Multicenter, randomized, double masked, controlled trial. Participants: Three
hundred forty six eyes of 346 patients with penetrating eye injury.
Method: Following primary repair, eyes were randomized to receive a 0.1 ml intracameral or
intravitreal injection of 40µg gentamycin and 45µg clindamycin (cases), versus intracameral
or intravitreal injection of 0.1ml balanced saline solution (controls). All patients
received standard prophylactic antibiotic therapy (systemic, subconjunctival and topical).
Main outcome measures: Occurrence of endophthalmitis within two weeks after primary repair.
Status | Completed |
Enrollment | 0 |
Est. completion date | December 2004 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 3 Years and older |
Eligibility |
Inclusion Criteria: - All patients with penetrating eye injuries referred to collaborating institutes for primary repair Exclusion Criteria: - Absence of light perception - presence of endophthalmitis at the time of initial evaluation - total corneal opacity - age under 3 years - severe intracameral hemorrhage - history of intraocular surgery and presence of a corneal ulcer - Monocular patients - the better eye in simultaneous bilateral injuries |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind
Country | Name | City | State |
---|---|---|---|
Iran, Islamic Republic of | Ophthalmic Research Center | Tehran |
Lead Sponsor | Collaborator |
---|---|
hahid Beheshti University of Medical Sciences |
Iran, Islamic Republic of,
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04214821 -
The Pharmacokinetics of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%
|
Phase 1/Phase 2 | |
Completed |
NCT00461656 -
Povidone-iodine Antisepsis for Strabismus Surgery
|
Phase 4 | |
Completed |
NCT00136344 -
Study of Antibiotic Prophylaxis for Endophthalmitis Following Cataract Surgery
|
N/A | |
Completed |
NCT04568213 -
Hypochlorous Acid Disinfection Prior to Cataract Surgery
|
Phase 3 | |
Terminated |
NCT01496794 -
Endophthalmitis Cultures
|
N/A | |
Completed |
NCT00406913 -
Prophylaxis Prior to Cataract Surgery Conjunctival Flora and Optimal Ocular Sterilization Technique Prior to Cataract Surgery
|
N/A | |
Recruiting |
NCT05079854 -
Use Of Intracameral Moxifloxacin For Prophylaxis Of Open Globe Endophthalmitis
|
Phase 4 | |
Recruiting |
NCT05432336 -
Complex Ocular Infection, Optimization of Microbiological Diagnosis
|
||
Recruiting |
NCT02810587 -
Endophthalmitis After Intravitreous Anti-VEGF Injections in Patients Receiving vs. Not Receiving Topical Antibiotics
|
N/A | |
Recruiting |
NCT04035369 -
Endophthalmitis Post Intravitreal Injections
|
N/A | |
Not yet recruiting |
NCT03420820 -
Concentrating on Antisepsis: 5% vs. 10% Povidone-Iodine Prior to Intravitreal Injection
|
N/A | |
Recruiting |
NCT06268561 -
Ozurdex Endophtamitis Cohort, Prognostic Assessment at 12 Months
|
||
Withdrawn |
NCT00335231 -
Preoperative Topical Gatifloxacin on Anterior Chamber Cultures After Cataract Surgery
|
N/A | |
Not yet recruiting |
NCT03244072 -
Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery
|
Phase 2/Phase 3 | |
Completed |
NCT01323868 -
Endogenous Endophthalmitis in the Inpatient Setting
|
N/A | |
Completed |
NCT03363295 -
Evaluation of Macular Changes After Intracameral Moxifloxacin for Prevention of Endophthalmitis
|
Phase 4 | |
Suspended |
NCT02590523 -
Intracameral Antibiotic Safety Study
|
Phase 3 | |
Terminated |
NCT02770729 -
Evaluation of Efficacy and Safety of Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis.
|
Phase 3 | |
Not yet recruiting |
NCT02324166 -
Cefazolin-Lidocaine Combination Solution to Reduce Antibiotic Pain
|
Phase 4 | |
Completed |
NCT02595359 -
Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis
|
Phase 2 |